INTRODUCTION
This case study examines how OrganaBio’s unique Hub Processing Model successfully addressed the critical needs of two multinational pharmaceutical companies conducting mRNA vaccine trials for COVID-19, influenza, and RSV. The Sponsors required a cell processing partner with expertise in:
- Maintaining stringent quality and process controls: OrganaBio achieved a near-flawless 99.9% processing success rate across 1,400+ samples.
- Scaling processing capacity for dynamic schedules: Turnaround time was reduced by 50% to an average of 3 hours, exceeding the Sponsors’ requirement of 6 hours.
- Reducing risk through client-centric project management: Dedicated teams ensured seamless collaboration and adherence to Sponsor specifications.
KEY BENEFITS
- Reduced processing time: Achieved an average of 150 minutes, significantly faster than industry standards and Sponsor requirements.
- High processing success rate: Maintained a 99.8% success rate through meticulous tracking and rapid processing.
- Cost-effective solutions: Reduced shipping costs, minimized processing costs, and streamlined project timelines.
- Timely project execution: Reduced SOW turnaround time from 21 days to 24 hours.
CONCLUSION
OrganaBio’s Hub Processing Model offers a proven and efficient solution for cell processing in clinical trials. With dedicated teams and vertically integrated facilities, OrganaBio delivers high-quality, cost-effective services while reducing complexity and risk. This case study highlights OrganaBio’s commitment to supporting drug developers across the globe.